EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal–external validation

Takashi Saito iD, Keiritsu Sho, Tsukasa Saida iD, Taisuke Sumiya iD, Keiichiro Baba, Motohiro Murakami, Haruko Numajiri, Ayumi Shikama, Masashi Mizumoto iD, Kazushi Maruo iD, Akinori Oki, Toshiyuki Okumura und 3 weitere

Journal of Radiation Research · 2026

DOI: 10.1093/jrr/rrag043 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Radiation Research, 2026. Verfasst von Takashi Saito und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Chemoradiotherapy, Magnetic Resonance Imaging, Tumor Burden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (C).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to quantify the continuous association of the mid-treatment MRI-based tumor volume reduction rate (TVRR) with oncologic outcomes after chemoradiation for cervical cancer and to develop prognostic models assessed by two-center internal-external cross-validation (IECV). A retrospective analysis was performed in patients with FIGO 2009 stage IB–IVA disease treated with definitive chemoradiation at two centers from 2010 to 2021 with both pre- and mid-treatment pelvic MRI during external beam radiotherapy (24–36 Gy). Pre- and mid-treatment volumes (Vpre, Vmid) were derived and TVRR was defined as (Vpre − Vmid)/Vpre × 100%. Cox models were used to evaluate overall survival (OS) and progression-free survival (PFS), and a Fine-Gray model was used for local control (LC), modeling TVRR with a penalized spline and adjusting for key covariates. IECV assessed discrimination and 60-month calibration for OS and PFS. The analysis included 281 patients (median age 59 years; squamous cell carcinoma 85%; FIGO 2009 stage III–IV 60%; node-positive 56%) with 65 deaths, 97 PFS events, and 27 local failures over a median follow-up period of 69.6 months. Higher TVRR was independently associated with better outcomes: per 10-percentage-point (pp) increase, OS hazard ratio (HR) 0.71 (95% CI, 0.64–0.79; P < 0.001), PFS HR 0.74 (0.68–0.81; P < 0.001), and LC subdistribution HR 0.68 (0.58–0.80; P < 0.001). Non-linear components were not significant. Discrimination was moderate-high (C 0.73–0.81 internally; 0.72–0.79 in IECV) with acceptable 60-month calibration. In conclusion, mid-treatment MRI-based TVRR provides a strong, near-linear prognostic signal and enables threshold-free, calibrated risk estimation and supports design of risk-adapted trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsChemoradiotherapyMagnetic Resonance ImagingTumor BurdenHumansFemalePrognosisMiddle AgedRetrospective StudiesAgedTreatment OutcomeAdult

Stichwörter der Autor:innen

brachytherapychemoradiotherapymagnetic resonance imagingprognostic modelstumor volume reduction rateuterine cervical neoplasms

Autor:innen und Institutionen

  • Department of Radiation Oncology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
  • Department of Diagnostic and Interventional Radiology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
  • Department of Radiation Oncology, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309-1793, Japan.
  • Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
  • Department of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.
  • Department of Obstetrics and Gynecology, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309-1793, Japan.

ORCID-Profile: Takashi Saito, Tsukasa Saida, Taisuke Sumiya, Masashi Mizumoto, Kazushi Maruo, Hideyuki Sakurai

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (C)

Zitieren

APA

Saito, T., Sho, K., Saida, T., Sumiya, T., Baba, K., Murakami, M., Numajiri, H., Shikama, A., Mizumoto, M., Maruo, K., Oki, A., Okumura, T., Tamaki, Y., Satoh, T., & Sakurai, H. (2026). Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal–external validation. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrag043

Vancouver

Saito T, Sho K, Saida T, Sumiya T, Baba K, Murakami M, et al. Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal–external validation. Journal of Radiation Research. 2026. doi:10.1093/jrr/rrag043

BibTeX
@article{Saito2026,
  author = {Saito, Takashi and Sho, Keiritsu and Saida, Tsukasa and Sumiya, Taisuke and Baba, Keiichiro and Murakami, Motohiro and Numajiri, Haruko and Shikama, Ayumi and Mizumoto, Masashi and Maruo, Kazushi and Oki, Akinori and Okumura, Toshiyuki and Tamaki, Yoshio and Satoh, Toyomi and Sakurai, Hideyuki},
  title = {Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal–external validation},
  journal = {Journal of Radiation Research},
  year = {2026},
  doi = {10.1093/jrr/rrag043}
}
Kostenlos starten →